Caribou Biosciences (CRBU) Files 8-K Report

Ticker: CRBU · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1619856

Caribou Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyCaribou Biosciences, INC. (CRBU)
Form Type8-K
Filed DateJun 3, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-update, filing

Related Tickers: CRBU

TL;DR

CRBU filed an 8-K updating its office address and confirming NASDAQ listing.

AI Summary

On June 2, 2024, Caribou Biosciences, Inc. (CRBU) filed an 8-K report. The filing indicates the company's principal executive offices are located at 2929 7th Street, Suite 105, Berkeley, California, 94710. Caribou Biosciences' common stock is traded on the NASDAQ Global Select Market under the symbol CRBU.

Why It Matters

This 8-K filing provides updated corporate information, including the company's principal executive office address and stock exchange listing, which are essential details for investors and stakeholders.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain material non-public information that would immediately impact the company's stock price.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information about Caribou Biosciences, Inc., including its principal executive offices and stock exchange listing.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 2, 2024.

Where are Caribou Biosciences, Inc.'s principal executive offices located?

Caribou Biosciences, Inc.'s principal executive offices are located at 2929 7th Street, Suite 105, Berkeley, California, 94710.

On which exchange is Caribou Biosciences, Inc. common stock traded?

Caribou Biosciences, Inc. common stock is traded on the NASDAQ Global Select Market.

What is the trading symbol for Caribou Biosciences, Inc. on the NASDAQ?

The trading symbol for Caribou Biosciences, Inc. on the NASDAQ is CRBU.

Filing Stats: 785 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-06-03 06:01:56

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 2, 2024, Caribou Biosciences, Inc. (the "Company") issued a press release announcing updated clinical data from the ongoing ANTLER Phase 1 trial for CB-010, an allogeneic, or off-the-shelf, anti-CD19 CAR-T cell therapy, being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma ("r/r B-NHL"). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01. The Company hosted a webcast on June 2, 2024, including a discussion with KOLs and Company management, on the CB-010 ANTLER Phase 1 data presentation. The archived audio webcast is available on the Company's website until July 2, 2024. A copy of the slide presentation used during the Company's webcast, which includes a summary of the initial dose expansion results of the ANTLER Phase 1 clinical trial, is attached hereto as Exhibit 99.2 and is incorporated by reference herein. The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing or other document under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing or document, except as shall be expressly set forth by specific reference in any such filing or document.

01 Other Events

Item 8.01 Other Events. On June 2, 2024, the Company announced updated clinical data from the ongoing ANTLER Phase 1 trial for CB-010, an allogeneic, or off-the-shelf, anti-CD19 CAR-T cell therapy, being evaluated in patients with r/r B-NHL and hosted a webcast, including a discussion with KOLs and Company management, on the CB-010 ANTLER Phase 1 data presentation. A copy of the slide presentation used during the Company's webcast, which includes a summary of the initial dose expansion results of the ANTLER Phase 1 clinical trial, is attached hereto as Exhibit 99.2 and is incorporated by reference herein. The clinical results are being presented during a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2024.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Caribou Biosciences, Inc. on June 2 , 2024 99.2 Caribou Biosciences, Inc. Webcast Slide Presentation dated June 2, 2024 Regarding CB-010 ANTLER Phase 1 Trial Update and KOL Discussion 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Caribou Biosciences, Inc. Date: June 3, 2024 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing